I was starting to think the flu-vax trial announcement was overdue based on my recent correspondance with the company, so I decided to ask for an update.
ME: 'I noticed there was no mention of the flu-vax trial during February or in the Half-Yearly Report. Are there any delays?'
PCC: 'No there are no delays. We deliberately left it out because we want to complete a technical paper on the results first, have it peer-reviewed and then published in a medical journal. To announce to ASX first would affect our ability to register a patent for any resulting IP. This should all be completed within a month or so.'
Therefore, whilst it will still be a little way off, which is always the way with PCC and companies like it, the vital clue here is that they plan to go to extensive levels to publish these results in a medical journal. Putting 2 and 2 together would suggest that these results are extremely encouraging, and will do the sp no harm in the lead-up to future sales results and further possible deals.
PCC Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held